

Francesca Fornari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4455691/publications.pdf>

Version: 2024-02-01

43
papers

4,752
citations

186265

28
h-index

265206

42
g-index

43
all docs

43
docs citations

43
times ranked

6454
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathophysiology roles and translational opportunities of miRNAs in hepatocellular carcinoma. , 2022, , 301-315.		0
2	Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area. <i>Nutrients</i> , 2022, 14, 1652.	4.1	6
3	MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma. <i>Biomolecules</i> , 2022, 12, 930.	4.0	2
4	Notch Signaling Regulation in HCC: From Hepatitis Virus to Non-Coding RNAs. <i>Cells</i> , 2021, 10, 521.	4.1	13
5	MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 369-385.	3.7	12
6	Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 741-757.	3.7	29
7	Hepatic Cancer Stem Cells: Molecular Mechanisms, Therapeutic Implications, and Circulating Biomarkers. <i>Cancers</i> , 2021, 13, 4550.	3.7	6
8	Direct Antiviral Treatments for Hepatitis C Virus Have Off-Target Effects of Oncologic Relevance in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 2674.	3.7	13
9	Association of <i>NOS3</i> and <i>ANGPT2</i> Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. <i>Clinical Cancer Research</i> , 2020, 26, 4485-4493.	7.0	13
10	MiR-30e-3p Influences Tumor Phenotype through <i>MDM2</i> / <i>TP53</i> Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2020, 80, 1720-1734.	0.9	47
11	Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming. <i>Journal of Hepatology</i> , 2020, 72, 1159-1169.	3.7	38
12	MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2019, 8, 171.	2.4	37
13	MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 14, 239-250.	5.1	14
14	Animal Models of Hepatocellular Carcinoma Prevention. <i>Cancers</i> , 2019, 11, 1792.	3.7	10
15	MicroRNAs in Animal Models of HCC. <i>Cancers</i> , 2019, 11, 1906.	3.7	25
16	MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma. <i>Acta Histochemica</i> , 2018, 120, 95-102.	1.8	22
17	The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2018, 9, 4.	6.3	68
18	LncRNAs as novel players in hepatocellular carcinoma recurrence. <i>Oncotarget</i> , 2018, 9, 35085-35099.	1.8	46

#	ARTICLE	IF	CITATIONS
19	Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 15350-15364.	1.8	79
20	In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis. <i>Clinical Cancer Research</i> , 2017, 23, 3953-3965.	7.0	137
21	Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis. <i>Oncotarget</i> , 2016, 7, 32375-32393.	1.8	83
22	TP53/MicroRNA Interplay in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2029.	4.1	26
23	The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival. <i>Journal of Hepatology</i> , 2016, 64, 891-898.	3.7	34
24	Direct relationship between the level of p53 stabilization induced by rRNA synthesis-inhibiting drugs and the cell ribosome biogenesis rate. <i>Oncogene</i> , 2016, 35, 977-989.	5.9	44
25	Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 31361-31371.	1.8	45
26	Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC. <i>PLoS ONE</i> , 2015, 10, e0141448.	2.5	113
27	Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats. <i>Hepatology</i> , 2015, 61, 249-259.	7.3	63
28	p53/mdm2 Feedback Loop Sustains miR-221 Expression and Dictates the Response to Anticancer Treatments in Hepatocellular Carcinoma. <i>Molecular Cancer Research</i> , 2014, 12, 203-216.	3.4	43
29	Significance of serum and hepatic microRNA levels in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2014, 34, e302-7.	3.9	124
30	The Natural Inhibitor of DNA Topoisomerase I, Camptothecin, Modulates HIF-1 α Activity by Changing miR Expression Patterns in Human Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 239-248.	4.1	63
31	Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. <i>Oncotarget</i> , 2014, 5, 10607-10620.	1.8	39
32	Anti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus. <i>PLoS ONE</i> , 2013, 8, e73964.	2.5	53
33	CDKN1C/P57 Is Regulated by the Notch Target Gene Hes1 and Induces Senescence in Human Hepatocellular Carcinoma. <i>American Journal of Pathology</i> , 2012, 181, 413-422.	3.8	58
34	In hepatocellular carcinoma miR-519d is upregulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. <i>Journal of Pathology</i> , 2012, 227, 275-285.	4.5	180
35	Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. <i>Hepatology</i> , 2012, 56, 1025-1033.	7.3	150
36	Design, synthesis and biological evaluation of pyrazole derivatives as potential multi-kinase inhibitors in hepatocellular carcinoma. <i>European Journal of Medicinal Chemistry</i> , 2012, 48, 391-401.	5.5	29

#	ARTICLE	IF	CITATIONS
37	MiR-199a-3p Regulates mTOR and c-Met to Influence the Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. <i>Cancer Research</i> , 2010, 70, 5184-5193.	0.9	389
38	Oncogenic Role of <i>miR-483-3p</i> at the <i>IGF2/483</i> Locus. <i>Cancer Research</i> , 2010, 70, 3140-3149.	0.9	272
39	MicroRNA-221 Targets Bmf in Hepatocellular Carcinoma and Correlates with Tumor Multifocality. <i>Clinical Cancer Research</i> , 2009, 15, 5073-5081.	7.0	298
40	MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. <i>Cancer Research</i> , 2009, 69, 5761-5767.	0.9	380
41	MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. <i>Oncogene</i> , 2008, 27, 5651-5661.	5.9	619
42	MicroRNA involvement in hepatocellular carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 2189-2204.	3.6	248
43	Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma. <i>Cancer Research</i> , 2007, 67, 6092-6099.	0.9	782